{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:47:23Z","timestamp":1768524443294,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2023,1,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The association between cutaneous melanoma and subsequent risk of prostate cancer (PC) was examined in a large population-based cohort study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Male participants in the Sax Institute\u2019s 45 and Up Study (Australia) were recruited between 2006 and 2009. Questionnaire data and linked administrative health data from the Centre for Health Record Linkage and Services Australia identified melanomas diagnosed between 1\/1\/1994 and 12 months before Study recruitment (i.e., between 2005 and 2008), incident PCs, primary healthcare utilisation and prostate-specific antigen (PSA) tests. Men were excluded from the current analyses if they had a recorded PC or other cancer diagnosis other than melanoma and non-melanoma skin cancer prior to recruitment. Multivariable Cox regression was used to\u00a0estimate hazard ratios (HRs) adjusting for PSA-testing frequency before PC diagnosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 96,548 eligible men, 1899 were diagnosed with melanoma during the melanoma diagnosis period and 3677 incident PC diagnosed during follow-up (latest date 31\/12\/2013). Men with melanoma diagnosis had increased risk of a subsequent PC diagnoses (vs. no melanoma; fully adjusted HR\u2009=\u20091.32; 95% CI: 1.09\u20131.60). There was weak evidence of higher risks of a subsequent PC diagnosis for men diagnosed with more than one melanoma compared to men diagnosed with only one melanoma (<jats:italic>p<\/jats:italic>\u2009=\u20090.077), and if first melanoma diagnosis was 10 to 15 years before Study recruitment (fully adjusted HR\u2009=\u20092.05; 95% CI [1.35, 3.12]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Melanoma diagnosis was associated with increased risk of subsequent PC diagnosis, after adjusting for PSA testing and primary healthcare utilisation. While our ability to adjust for PC screening reduced risk of detection bias, we acknowledge that residual confounding from increased medical surveillance after melanoma diagnoses cannot be entirely ruled out.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-022-02027-7","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T11:03:06Z","timestamp":1667300586000},"page":"71-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cutaneous melanoma, prostate-specific antigen testing and the subsequent risk of prostate cancer diagnosis: a prospective analysis of the 45 and Up Study"],"prefix":"10.1038","volume":"128","author":[{"given":"Sam","family":"Egger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1474-3214","authenticated-orcid":false,"given":"David P.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish I.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Kimlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce K.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6277-5125","authenticated-orcid":false,"given":"Visalini","family":"Nair-Shalliker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"2027_CR1","unstructured":"Welfare, AIHW. Cancer in Australia 2019. Cancer series no.119. Cat. no. CAN 123. Canberra:\u2009AIHW;\u20092019. https:\/\/www.aihw.gov.au\/getmedia\/8c9fcf52-0055-41a0-96d9-f81b0feb98cf\/aihw-can-123.pdf.aspx?inline=true Date accessed: October 2022."},{"key":"2027_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209\u201349.","journal-title":"Cancer J Clin"},{"key":"2027_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/ijc.31527","volume":"143","author":"M Arnold","year":"2018","unstructured":"Arnold M, de Vries E, Whiteman DC, Jemal A, Bray F, Parkin DM, et al. Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012. Int J Cancer. 2018;143:1305\u201314.","journal-title":"Int J Cancer"},{"key":"2027_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/00008390-199311000-00002","volume":"3","author":"BK Armstrong","year":"1993","unstructured":"Armstrong BK, Kricker A. How much melanoma is caused by sun exposure? Melanoma Res. 1993;3:395\u2013401.","journal-title":"Melanoma Res"},{"key":"2027_CR5","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ejca.2012.11.001","volume":"49","author":"H van der Rhee","year":"2013","unstructured":"van der Rhee H, Coebergh JW, de Vries E. Is prevention of cancer by sun exposure more than just the effect of vitamin D? A systematic review of epidemiological studies. Eur J Cancer (Oxf, Engl: 1990). 2013;49:1422\u201336.","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"key":"2027_CR6","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.7314\/APJCP.2012.13.7.3179","volume":"13","author":"SE Chia","year":"2012","unstructured":"Chia SE, Wong KY, Cheng C, Lau W, Tan PH. Sun exposure and the risk of prostate cancer in the Singapore Prostate Cancer Study: a case-control study. Asian Pac J Cancer Prev. 2012;13:3179\u201385.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2027_CR7","doi-asserted-by":"publisher","first-page":"E726","DOI":"10.1002\/ijc.27400","volume":"131","author":"V Nair-Shalliker","year":"2012","unstructured":"Nair-Shalliker V, Smith DP, Egger S, Hughes AM, Kaldor JM, Clements M, et al. Sun exposure may increase risk of prostate cancer in the high UV environment of New South Wales, Australia: a case-control study. Int J Cancer. 2012;131:E726\u201332.","journal-title":"Int J Cancer"},{"key":"2027_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25408-6","volume":"8","author":"D Cole-Clark","year":"2018","unstructured":"Cole-Clark D, Nair-Shalliker V, Bang A, Rasiah K, Chalasani V, Smith DP. An initial melanoma diagnosis may increase the subsequent risk of prostate cancer: results from the New South Wales Cancer Registry. Sci Rep. 2018;8:7167.","journal-title":"Sci Rep"},{"key":"2027_CR9","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jid.2018.11.001","volume":"139","author":"MG Kimlin","year":"2019","unstructured":"Kimlin MG, Youlden DR, Brodie AM, DiSipio T, Youl P, Shalliker N. et al. Risk of second primary cancer in survivors of in situ melanoma. J Investig Dermatol. 2019;139:842\u20137.","journal-title":"J Investig Dermatol"},{"key":"2027_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-210","volume":"14","author":"TE Robsahm","year":"2014","unstructured":"Robsahm TE, Karagas MR, Rees JR, Syse A. New malignancies after squamous cell carcinoma and melanomas: a population-based study from Norway. BMC Cancer. 2014;14:210.","journal-title":"BMC Cancer"},{"key":"2027_CR11","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1002\/cam4.2995","volume":"9","author":"P Acharya","year":"2020","unstructured":"Acharya P, Mathur M. Prostate cancer risk in patients with melanoma: A systematic review and meta-analysis. Cancer Med. 2020;9:3604\u201312.","journal-title":"Cancer Med"},{"key":"2027_CR12","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/ije\/dym184","volume":"37","author":"E Banks","year":"2008","unstructured":"Banks E, Redman S, Jorm L, Armstrong B, Bauman A, Beard J, et al. Cohort profile: the 45 and up study. Int J Epidemiol. 2008;37:941\u20137.","journal-title":"Int J Epidemiol"},{"key":"2027_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-26","volume":"10","author":"NM Mealing","year":"2010","unstructured":"Mealing NM, Banks E, Jorm LR, Steel DG, Clements MS, Rogers KD. Investigation of relative risk estimates from studies of the same population with contrasting response rates and designs. BMC Med Res Methodol. 2010;10:26.","journal-title":"BMC Med Res Methodol"},{"key":"2027_CR14","unstructured":"CHeReL. https:\/\/www.cherel.org.au\/. CHeReL; 2022. Date accessed: October 2022"},{"key":"2027_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-149","volume":"12","author":"JP Bentley","year":"2012","unstructured":"Bentley JP, Ford JB, Taylor LK, Irvine KA, Roberts CL. Investigating linkage rates among probabilistically linked birth and hospitalization records. BMC Med Res Methodol. 2012;12:149.","journal-title":"BMC Med Res Methodol"},{"key":"2027_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676\u201382.","journal-title":"Am J Epidemiol"},{"key":"2027_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5694\/j.1326-5377.2006.tb00086.x","volume":"184","author":"MP Staples","year":"2006","unstructured":"Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust. 2006;184:6\u201310.","journal-title":"Med J Aust"},{"key":"2027_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/oxfordjournals.aje.a009034","volume":"145","author":"EL Korn","year":"1997","unstructured":"Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145:72\u201380.","journal-title":"Am J Epidemiol"},{"key":"2027_CR19","doi-asserted-by":"crossref","unstructured":"Kleinbaum DG, Klein M. The stratified cox procedure. In: David G Kleinbaum, Klein M, editors. Survival analysis: a self-learning text. New York, NY, Springer; 2012. p. 201\u2013240.","DOI":"10.1007\/978-1-4419-6646-9_5"},{"key":"2027_CR20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/aje\/kwg062","volume":"157","author":"NS Weiss","year":"2003","unstructured":"Weiss NS. Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it. Am J Epidemiol. 2003;157:957\u201361.","journal-title":"Am J Epidemiol"},{"key":"2027_CR21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-4632.2005.02640.x","volume":"45","author":"YH Wu","year":"2006","unstructured":"Wu YH, Kim GH, Wagner JD, Hood AF, Chuang TY. The association between malignant melanoma and noncutaneous malignancies. Int J Dermatol. 2006;45:529\u201334.","journal-title":"Int J Dermatol"},{"key":"2027_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdermsci.2014.02.007","volume":"75","author":"S Caini","year":"2014","unstructured":"Caini S, Boniol M, Botteri E, Tosti G, Bazolli B, Russell-Edu W, et al. The risk of developing a second primary cancer in melanoma patients: a comprehensive review of the literature and meta-analysis. J Dermatol Sci. 2014;75:3\u20139.","journal-title":"J Dermatol Sci"},{"key":"2027_CR23","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1200\/JCO.2013.51.1915","volume":"31","author":"WQ Li","year":"2013","unstructured":"Li WQ, Qureshi AA, Ma J, Goldstein AM, Giovannucci EL, Stampfer MJ, et al. Personal history of prostate cancer and increased risk of incident melanoma in the United States. J Clin Oncol. 2013;31:4394\u20139.","journal-title":"J Clin Oncol"},{"key":"2027_CR24","first-page":"295","volume":"58","author":"AB Hill","year":"1965","unstructured":"Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295\u2013300.","journal-title":"Proc R Soc Med"},{"key":"2027_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/ijc.30471","volume":"140","author":"V Nair-Shalliker","year":"2017","unstructured":"Nair-Shalliker V, Yap S, Nunez C, Egger S, Rodger J, Patel MI, et al. Adult body size, sexual history and adolescent sexual development, may predict risk of developing prostate cancer: results from the New South Wales Lifestyle and Evaluation of Risk Study (CLEAR). Int J Cancer. 2017;140:565\u201374.","journal-title":"Int J Cancer"},{"key":"2027_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/sj.bjc.6605757","volume":"103","author":"G Severi","year":"2010","unstructured":"Severi G, Shannon BA, Hoang HN, Baglietto L, English DR, Hopper JL, et al. Plasma concentration of Propionibacterium acnes antibodies and prostate cancer risk: results from an Australian population-based case-control study. Br J Cancer. 2010;103:411\u20135.","journal-title":"Br J Cancer"},{"key":"2027_CR27","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/j.1365-2133.2003.05565.x","volume":"149","author":"G Severi","year":"2003","unstructured":"Severi G, Sinclair R, Hopper JL, English DR, McCredie MR, Boyle P, et al. Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors. Br J Dermatol. 2003;149:1207\u201313.","journal-title":"Br J Dermatol"},{"key":"2027_CR28","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/ijc.31192","volume":"142","author":"H Ugge","year":"2018","unstructured":"Ugge H, Udumyan R, Carlsson J, Andr\u00e9n O, Montgomery S, Davidsson S, et al. Acne in late adolescence and risk of prostate cancer. Int J Cancer. 2018;142:1580\u20135.","journal-title":"Int J Cancer"},{"key":"2027_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/cancers4020531","volume":"4","author":"C H\u00e4ggl\u00f6f","year":"2012","unstructured":"H\u00e4ggl\u00f6f C, Bergh A. The stroma-a key regulator in prostate function and malignancy. Cancers. 2012;4:531\u201348.","journal-title":"Cancers"},{"key":"2027_CR30","doi-asserted-by":"crossref","unstructured":"Ma, M, Ghosh, S, Tavernari, D, Katarkar, A, Clocchiatti, A, Mazzeo, L, et al. Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis. J Exp Med. 2021; 218:e20201137.","DOI":"10.1084\/jem.20201137"},{"key":"2027_CR31","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1158\/0008-5472.CAN-11-1988","volume":"71","author":"H Nan","year":"2011","unstructured":"Nan H, Du M, De Vivo I, Manson JE, Liu S, McTiernan A, et al. Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res. 2011;71:6758\u201363.","journal-title":"Cancer Res"},{"key":"2027_CR32","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/ijc.33416","volume":"148","author":"EL Watts","year":"2021","unstructured":"Watts EL, Fensom GK, Smith Byrne K, Perez-Cornago A, Allen NE, Knuppel A, et al. Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200\u2009000 men in UK Biobank. Int J Cancer. 2021;148:2274\u201388.","journal-title":"Int J Cancer"},{"key":"2027_CR33","doi-asserted-by":"publisher","unstructured":"Watts EL, Perez-Cornago A, Knuppel A, Tsilidis KK, Key TJ & Travis RC. Prospective analyses of testosterone and sex hormone-binding globulin with the risk of 19 types of cancer in men and postmenopausal women in UK Biobank. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.33555 (2021).","DOI":"10.1002\/ijc.33555"},{"key":"2027_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.abb.2014.06.018","volume":"563","author":"A Nosrati","year":"2014","unstructured":"Nosrati A, Wei ML. Sex disparities in melanoma outcomes: the role of biology. Arch Biochem Biophys. 2014;563:42\u201350.","journal-title":"Arch Biochem Biophys"},{"key":"2027_CR35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1071\/AH13092","volume":"37","author":"JA Trevena","year":"2013","unstructured":"Trevena JA, Rogers KD, Jorm LR, Churches T, Armstrong B. Quantifying under-reporting of pathology tests in Medical Benefits Schedule claims data. Aust health Rev. 2013;37:649\u201353.","journal-title":"Aust health Rev"},{"key":"2027_CR36","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1002\/ijc.29961","volume":"138","author":"FB Thomsen","year":"2016","unstructured":"Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, et al. Risk of malignant melanoma in men with prostate cancer: nationwide, population-based cohort study. Int J Cancer. 2016;138:2154\u201360.","journal-title":"Int J Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02027-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02027-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02027-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T11:07:31Z","timestamp":1672916851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02027-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,26]]}},"alternative-id":["2027"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-02027-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"assertion":[{"value":"3 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Individuals gave written informed consent to take part in the study, including consent for follow-up through repeated data collection and linkage of their data to population health databases. Ethical approval for the conduct of the 45 and Up Study was provided by the University of New South Wales Human Research Ethics Committee. Ethical approval for the present study was provided by the NSW Population & Health Services Research Ethics Committee (14\/CIPHS\/54).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}